FDA issues H1N1 warning letters
This article was originally published in The Tan Sheet
FDA warns Cashburners, the website manager and host site for Flu Defence dietary supplement - sold on fludefence.org, fludefence.net and swinefludefence.org - to stop marketing the supplement, because it is unapproved by FDA to diagnose, mitigate, prevent, treat or cure H1N1. In warning letters sent June 2 to the domain protector and website marketer located in New Zealand, the Netherlands and Westchester, Calif., the agency takes issue with claims including "[E]xhibits strong antiviral action against influenza A & 8, birdflu ... swine flu." FDA teamed with the Federal Trade Commission and foreign governments to root out improper claims regarding products that treat or prevent H1N1 flu (1"The Tan Sheet" Oct. 19, 2009). FDA also warned Nature's Gift in a letter posted June 11 to discontinue claims on its blog that Flu Foil Synergy, Flu Foil Synergy with Inhaler, Ravensara and Ravintsara could diagnose, mitigate, prevent, treat or cure H1N1 because the products are unapproved
You may also be interested in...
A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus
Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials
Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.
Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker